European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell L
Go back to European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell L| Merck & Co. (NYSE: MRK) | Delayed: 148.44 -0.34 (0.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.78 | 52 Week High | $65.46 | |||
| Open | $147.65 | 52 Week Low | $47.97 | |||
| Day High | $149.08 | P/E | 100.98 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 567,172 | |||||
